Research Radboud technology centers Radboud Biobank News Visibility of the Radboud Biobank
17 October 2019

It is essential to have a complete and up-to-date list of publications where the Radboud Biobank has provided source material and data.

This not only demonstrates the value of the Radboud Biobank as a central biobank facility but also strengthens the publication. The method section of the publication should contain the following reference: Manders et al. Radboud Biobank: a central facility for prospective clinical biobanking at the Radboud university medical center, Nijmegen. Open Journal of Bioresources, 2018; 5: 2. DOI: http://doi.org/10.5334/ojb.36. This also applies to publications resulting from projects that have used the storage facilities of the Radboud Biobank.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more